Skip to content

Trevi Therapeutics, Inc. TRVI Other operating expenses

Other operating expenses at other companies

Indivior Pharmaceuticals, Inc.
 logo
Indivior Pharmaceuticals, Inc. INDV
$139M-10.9%

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K
Free cash flow-$16.8M

Valuation

See full
Market cap$2.47B+152%
Enterprise value$2.45B+157%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0.0×
Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trevi Therapeutics, Inc.'s other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Trevi Therapeutics, Inc.'s other operating expenses?
Trevi Therapeutics, Inc. (TRVI) reported other operating expenses of 1,491,200,000% in Q1 2026.
How has Trevi Therapeutics, Inc.'s other operating expenses changed year-over-year?
Trevi Therapeutics, Inc.'s other operating expenses increased by 30.0% year-over-year, from 1,147,000,000% to 1,491,200,000%.
What is the long-term trend for Trevi Therapeutics, Inc.'s other operating expenses?
Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s other operating expenses has grown at a 11.8% compound annual growth rate (CAGR), from 5,667,900,000% to 8,843,600,000%.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.